Carbapenemase-producing Pseudomonas aeruginosa and ciprofloxcacin use in neonatal intensive care units

J Hosp Infect. 2003 Jun;54(2):164-5. doi: 10.1016/s0195-6701(03)00127-0.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Comment

MeSH terms

  • Anti-Infective Agents / therapeutic use*
  • Bacterial Proteins*
  • Central Nervous System / abnormalities
  • Ciprofloxacin / therapeutic use*
  • Cross Infection / drug therapy*
  • Cross Infection / microbiology*
  • Drug Resistance
  • Drug Utilization
  • Humans
  • Infant, Newborn
  • Infection Control
  • Intensive Care Units, Neonatal
  • Meningomyelocele / complications
  • Microbial Sensitivity Tests
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / microbiology*
  • Pseudomonas aeruginosa / enzymology*
  • beta-Lactamases / metabolism*

Substances

  • Anti-Infective Agents
  • Bacterial Proteins
  • Ciprofloxacin
  • beta-Lactamases
  • carbapenemase